hVIVO plc (LSE:HVO) recorded revenue of £24.2 million in the first half of 2025, with a full-year revenue forecast of £47 million. The recent acquisitions of CRS and Cryostore have expanded the company’s service portfolio and customer base, contributing £5.5 million to group revenue. Despite challenges specific to its sector, hVIVO maintains a strong sales pipeline and is focused on diversifying revenue streams and growing its clinical service offerings.
The company’s outlook benefits from solid financial performance and an attractive valuation, supported by positive corporate developments that signal strategic growth and leadership confidence. However, technical indicators advise some caution due to potential downward momentum.
More about Open Orphan Plc
hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials. It delivers comprehensive clinical development services to a broad and growing client base, including seven of the world’s ten largest biopharmaceutical companies.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply